GlassScriptPhysician profile
Amjad I Sheikh
NPI 1851326110
$3,736.74
in general payments reported to CMS, 2019-2025
23 companies · $67.57 in 2025
The $67.57 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $1,273 · 2021: $720 · 2022: $432 · 2023: $594 · 2024: $253 · 2025: $67.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.04 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $664.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $509.54 | 2019-2024 | Opsumit |
| Sanofi-Aventis U.S. LLC | $494.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $247.31 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $242.25 | 2019-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.47 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $226.69 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.71 | 2021-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $147.85 | 2019-2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $136.02 | 2021-2022 | |
| Medtronic, INC. | $108.65 | 2023-2025 | Symplicity G3, Onyx Frontier, Crome Dr Mri Surescan |
| Pfizer INC. | $78.54 | 2021-2024 | |
| Astellas Pharma US INC | $65.96 | 2019-2021 | |
| Edwards Lifesciences Corporation | $60.75 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $52.27 | 2023 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $46.83 | 2021 | |
| Esperion Therapeutics, INC. | $46.27 | 2021 | |
| Lantheus Medical Imaging, INC. | $45.50 | 2022-2024 | |
| Amgen INC. | $37.77 | 2024-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $33.62 | 2024 | Arcalyst |
| Boston Scientific Corporation | $23.83 | 2023 | Watchman Access System |
| Biotronik INC. | $22.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.